In 2026, some of the key industry trends essential to company success and maintaining stability include long-lasting ...

Driven by the growing prevalence of chronic diseases, the need for convenient and cost-effective drug delivery solutions, and ...

Sales growth was driven by both US Operations and International Operations. The volume growth of the global branded GLP-1 ...

“The global API manufacturing market is going through some major changes these days,” says Sean O’Brien, COO, Abzena. He ...

Charles River Laboratories will close its cell therapy contract development and manufacturing site in Hanover, Md., ...

Acquired business specializes in lab-based research services using human tissue across preclinical and clinical settings.

OXB and Bristol Myers Squibb (BMS) are expanding a partnership regarding manufacture and supply of lentiviral vectors for BMS’ CAR-T programs.

Pharmaceutical sales were $14.8 billion, up 6% in the quarter. Comments: Pharmaceutical sales were $14.8 billion, up 6%. The increase was primarily driven by growth in oncology as well as ...

Biomica, a subsidiary of Evogene, and Lishan Biotech have agreed to a worldwide, exclusive licensing deal for a microbiome-based therapeutic.

Bracco Imaging is expanding into the cell therapy space to explore new applications of its long-established microbubble technology.

HighRes Biosolutions and Opentrons Labworks are launching a partnership to develop an AI agent-to-agent laboratory automation workflow.

BioMed X, an innovation hub for pharma with headquarters in Heidelberg, has appointed Nico Frisch as Vice President, Site Head Heidelberg.